Koning Health’s Response to the Recent USPSTF Breast Imaging Guidelines

Koning has reviewed the updated breast cancer imaging guidelines issued by the US Preventive Services Task Force (USPSTF), recommending biennial screening for women aged 40 to 74. While we appreciate lowering the starting age from 50 to 40, Koning Health respectfully disagrees with the frequency of exams mentioned in the guidelines; we stand with the Society of Breast Imaging (SBI), the American College of Radiology (ACR), and the American Cancer Society (ACS) in advocating for annual scans beginning at age 40.

Here’s Where They Have It Wrong and Here’s Why:

The USPSTF’s recommendation underestimates the significant benefits of early detection through more frequent exams. Annual imaging has been proven to increase cancer detection rates, particularly in the critical 40-49 age group, where the incidence of breast cancer is well-documented and on the rise. By extending the interval between exams to two years, we risk delaying the diagnosis of breast cancer in many women, potentially impacting their prognosis and overall health outcomes.

Improve Outcomes, Reduce Cost:

Frequent exams not only save lives but are also cost-effective in the long term. Early detection typically leads to less invasive treatments, which are generally less expensive and less burdensome for patients and healthcare systems alike. Annual exams ensure that cancers are caught earlier, often before they have spread, which can significantly reduce treatment costs and improve patient outcomes.

Our Alignment with Leading Organizations:

We wholeheartedly support the guidelines established by esteemed organizations such as SBI, ACR, and ACS, all of which recommend annual exams starting at age 40. Additionally, we recognize the critical importance of supplemental imaging, particularly for women with dense breasts. 

Innovative Breast Cancer Imaging: 

Regarding diagnostic imaging, Koning proudly offers a groundbreaking alternative with our Koning Vera Breast CT technology. As the pioneers of the first no-compression Breast CT, we provide a low-dose, true 3D imaging solution that stands as a testament to our commitment to innovation and patient comfort. 

Our extensive studies and ongoing research consistently demonstrate that Breast CT without contrast is equal to or surpasses traditional mammography in diagnostic accuracy. Furthermore, with contrast, it rivals the effectiveness of MRI, offering a quicker, more comfortable and less invasive option which many find painful and deterring.

By championing annual exams and offering advanced diagnostic solutions, Koning Health remains dedicated to advancing breast cancer imaging technologies and enhancing the health outcomes of women worldwide. We urge healthcare providers, policymakers, and insurance companies to consider these points and recognize the importance of annual breast exams. 

Koning is proud to contribute to this vital cause and we stand by our commitment to provide excellence in breast cancer care.